AmerisourceBergen

The second largest drug distributor in the U.S. held steady on this year’s list with 6.9% revenue growth in its 2019 fiscal year, driven primarily by strong sales of pricey specialty drugs. Profits were down due to impairment charges taken on PharMEDium, the company’s troubled compounding unit; AmerisourceBergen announced it was shuttering the business earlier this year. Like its competitors, AmerisourceBergen faces thousands of lawsuits and a federal criminal investigation over its alleged role in the nation’s opioid epidemic. States rejected a proposed $18 billion settlement with the three major drug wholesalers in February.